Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.43 |
| ▸ | CTSS | P25774 | 13/20 | 0.42 |
| ▸ | CTSK | P43235 | 11/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | CTSB | P07858 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5048335 | 0.90 | CTSL (0.43) | CTSLCTSSCTSKHDAC4HDAC1 | |
| SCHEMBL5048251 | 0.86 | CTSL (0.42) | CTSLCTSSCTSKHDAC4HDAC1 | |
| SCHEMBL3817398 | 0.84 | CTSL (0.46) | CTSLCTSSCTSKHDAC4HDAC1 | |
| SCHEMBL6477869 | 0.77 | CTSL (0.42) | CTSLCTSSCTSKHDAC4HDAC1 | |
| SCHEMBL3827244 | 0.74 | CTSS (0.43) | CTSLCTSSCTSKHDAC4HDAC1 | |
| SCHEMBL3827241 | 0.74 | CTSL (0.45) | CTSLCTSSCTSKHDAC4HDAC1 | |
| SCHEMBL15086641 | 0.73 | HDAC4 (0.41) | CTSLCTSSCTSKHDAC4HDAC1 | |
| SCHEMBL6503858 | 0.73 | CTSL (0.76) | CTSLCTSSCTSKCTSB | |
| SCHEMBL12070307 | 0.72 | HDAC4 (0.41) | CTSLCTSSCTSKHDAC4HDAC1 | |
| SCHEMBL6493540 | 0.71 | CTSL (0.69) | CTSLCTSSCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368424-B2 | Acylated nonadepsipeptides | AICURIS GMBH & CO. KG (DE) | 2008-05-06 | — | — | US | disclosed |
| US-7368424-B2 | Acylated nonadepsipeptides | AICURIS GMBH & CO. KG (DE) | 2008-05-06 | — | — | US | disclosed |
| US-7368424-B2 | Acylated nonadepsipeptides | AICURIS GMBH & CO. KG (DE) | 2008-05-06 | — | — | US | disclosed |
| US-20050075281-A1 | peptide antibiotics comprising lysobactin derivatives used for treatment and/or prophylaxis of bacterial infectious diseases; cyclic peptides | BAYER HEALTHCARE AG (DE) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075281-A1 | peptide antibiotics comprising lysobactin derivatives used for treatment and/or prophylaxis of bacterial infectious diseases; cyclic peptides | VIP, LNPEP, HAMP | CTSL 65/4885CTSS 459/4885CTSK 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.